We also found that in lung cancer patients receiving neoadjuvant immunotherapy, more infiltrated CD3+, CD4+, CD8+, or CD68+ cells were detected in pre-treatment tumor tissues from patients achieving pathologic complete response (pCR) (Supplementary Fig. 1H). This evidence concerns the gene CD4 and lung carcinoma.